Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Lipid-Lowering Therapy on Coronary Plaque Progression in Chronic Coronary Syndrome
NCT06896708Recruiting
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in Chronic Coronary Syndrome (CCS) (2 arms). Primary endpoint: Composite events of atherosclerotic plaque progression at 12 months. Started Aug 2025; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT06896708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896708.